Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + SBRT in Malignant Pleural Mesothelioma
NCT04166734Phase 1Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in malignant pleural mesothelioma (MPM) (2 cohorts), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Dose Limiting Toxicity at 12 weeks. Started Feb 2021; status: terminated.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04166734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166734.